Aldeyra Therapeutics, Inc.ALDXNASDAQ
LOADING
|||
R&D Expense Growth Accelerating
Trending higher, above historical average, slight contraction.
Left:
||||
Year-over-year research & development expense growth
Latest
63.70%
↑ 58% above average
Average (9y)
40.26%
Historical baseline
Range
High:104.26%
Low:-44.35%
CAGR
-5.3%
Structural decline
| Period | Value |
|---|---|
| 2024 | 63.70% |
| 2023 | -37.73% |
| 2022 | 5.27% |
| 2021 | 82.07% |
| 2020 | -44.35% |
| 2019 | 48.72% |
| 2018 | 82.93% |
| 2017 | 23.73% |
| 2016 | 73.96% |
| 2015 | 104.26% |